PSI Journal Club: Limitations and Challenges with Mixed Model Repeated Measures (MMRM) Analysis
Moses Mwangi and Florian Lasch present their recent work on MMRM, with discussion lead by Geert Molenberghs.
Time: 14:00 - 15:00 (UK Time)
Chair: Dr. Bernd-Wolfgang Igl (Boehringer Ingelheim Pharma GmbH & Co. KG)
Published in: Regulatory Toxicology and Pharmacology 96 (2018) 94–105; https://doi.org/10.1016/j.yrtph.2018.04.018)
Matthew Clark, Scientific Services, R&D Solutions, Elsevier, Philadelphia, USA & Thomas Steger-Hartmann, Investigational Toxicology, Bayer AG, Berlin, Germany
Attrition of drug candidates in clinical trials due to safety issues still contributes to a significant part of project closures besides other reasons such as the lack of efficacy, PK issues or strategic reasons. While failure of a candidate during preclinical development is a reflection of the primary task of the functions involved in this phase (i.e. toxicology, safety pharmacology and DMPK), failures during the later clinical phases often raise the question whether the preclinical safety studies are sufficiently predictive for the human outcome. Due to the fact that the First-in-Man study requires pivotal animal studies normally performed in two species, the focus of analysis of the debated predictivity centers around these animal studies. After the seminal study from Olson et al. (2000) numerous publications have shown that animal toxicity studies are predictive to a certain extent and that the predictivity varies among endpoints, some of them such as hematological, gastrointestinal, and cardiovascular events being better predicted than others (e.g. cutaneous adverse events). Most of these analyses compared the preclinical – clinical correlation for a rather limited set of compounds (<150) or for specific field of indications. The authors will present the results of this purely statistical approach based on data available for 3290 compounds in the commercial database Pharmapendium. The work provides answers to the implication of an observation in an animal for human risk and more specifically to the question whether concordance, i.e. the translatability of an observation from animal to human is dependent on the animal species. The statistical methods and procedures will be described in detail.
Registration has now closed.
Moses Mwangi and Florian Lasch present their recent work on MMRM, with discussion lead by Geert Molenberghs.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Talks from speakers will cover an introduction to HTA and indirect comparisons for value assessment before focusing in more specifically on topics related to the use of indirect treatment comparisons for patient access.
Talks from the speakers will cover the use of R in a programming community, submitted to regulators using R, and also programming beyond R in C++ and Julia.
This course is aimed at clinical trial statisticians who are new to or with limited experience of machine learning. Attendees will learn about a range of topics in machine learning, including practical sessions in R.
This webinar will explore two different approaches to Correlates of Protection in vaccine development.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.